The 1st No CompromiseSolution in Cataract Surgery
OPIRA™ is an intraocular lens designed to provide a full range of vision with monofocal optical quality
Current lenses have limitations
Cataract surgery has restored clear distance vision for millions of people — but seeing up close still means reading glasses or compromise. Today's presbyopia-correcting IOLs reduce dependence on glasses by splitting or stretching light across multiple focal points, a design trade-off that can cost patients contrast and crisp night vision.
Glare and Halo
Spectacle Dependance
Poor Image Quality
Restoring natural vision
The OPIRA™ intraocular lens' patented technology harnesses the eye's own focusing mechanism to dynamically change the curvature of the lens implant and restore a full, continuous range of vision.
See how it comparesOPIRA™ IOL
OPIRA™ is positioned to expand the premium market by removing the side effects that have limited adoption of presbyopic lenses.
| Monofocal | Multifocal | EDOF | OPIRA™ | |
|---|---|---|---|---|
| Distance vision | ||||
| Near vision | ||||
| Freedom from glare & halos |
OPIRA™ is an investigational device. Characteristics shown are design intent. Visual results from 30 subject cohort. Additional studies required to confirm results.
A team that is redefining the premium IOL field
Led by seasoned ophthalmic medical device experts and proven venture builders, our team combines deep clinical and technical expertise with a track record of taking companies from concept to successful exit.
Eugene De Juan Jr., MD
Founder & Chief Executive Officer
Dr. Eugene De Juan Jr. is one of ophthalmology's most prolific inventors and founder of the ForSight Labs incubator; holds a Distinguished Chair in Ophthalmology at UCSF. Named on 50+ device patents across 100+ products, with prior ForSight "VISION" ventures acquired by QLT, Roche / Genentech, and Allergan.
Ayman Naseri, MD
President & Chief Medical Officer
Dr. Ayman Naseri is a cataract and refractive surgeon and a Professor and former Vice-Chair of Ophthalmology at UCSF. With almost a decade of business leadership experience he brings a rare combination of clinical expertise and first-hand understanding of physician, patient, and market needs.
Guy Oren, MS
Chief Technology Officer
Guy Oren brings 25+ years of senior technology leadership specialized in polymer-based medical devices, including experience with design control, manufacturing scale-up and FDA readiness processes. Guy holds a BS in Chemical Engineering and an MS in Management.
Shirley Kleinman, MBA
Chief Financial Officer
Shirley Kleinman brings 15 years of financial leadership in ophthalmic and digital-health medical device startups, from clinical stage to full commercialization. Shirley holds a BA in Economics and Sociology and an MBA.
Matt Clarke, MS
VP of Operations
Matt Clarke has held senior operations roles across the ForSight family of companies since 2009, spanning the full scope of ophthalmic device development from R&D through commercialization. Matt holds a BS in Chemistry and MS Polymer Science.
Paul Rhee, OD
VP of Clinical
Dr. Paul Rhee brings nearly two decades of ophthalmic medical device experience and 20+ years in eye care as a residency-trained optometrist, having led clinical development programs from early feasibility through regulatory approval. Paul holds a BS in Biology and an OD.
Nicole Kahn-Dror, MS
Director of R&D
Nicole Kahn-Dror brings over a decade of experience in product design and development in the ophthalmic medical device industry. Nicole holds BS degrees in Chemistry and Chemical Engineering and an MS in Chemical Engineering.
Join us in shaping the future of ophthalmology
We invite potential strategic partners and investors to connect with our team and learn more about our upcoming milestones.
info@forsightv6.comCorporate headquarters
ForSight VISION6, Inc. 6000 Shoreline Court, Suite 206South San Francisco, CA 94080
United States
Israel office
FSV6 Ltd. Maskit St 15Herzliya
Israel